Table 3.
Estimates of ocular chlamydia infection and clinically active trachoma
| Community | Functionality | Baseline prevalence, 0–9 years | Twenty four-month prevalence, 0–5 years | ||
|---|---|---|---|---|---|
| TF ± TI | Chlamydia | TF ± TI | Chlamydia | ||
| Hand-dug well | |||||
| 1 | Year-round | 29/58 (50%) | 0/42 (0%) | 21/31 (68%) | 2/31 (6%) |
| 2 | Year-round | 26/56 (46%) | 0/56 (0%) | 24/37 (65%) | 12/37 (32%) |
| 3 | Year-round | 10/50 (20%) | 0/50 (0%) | 8/16 (50%) | 0/16 (0%) |
| 4 | Wet season | 11/37 (30%) | 0/37 (0%) | 8/17 (47%) | 0/17 (0%) |
| 5 | Wet season | 7/37 (19%) | 0/37 (0%) | 8/16 (50%) | 0/16 (0%) |
| 6 | First 3 mos | 6/36 (17%) | 0/36 (0%) | 7/18 (39%) | 0/18 (0%) |
| 7 | Never | 32/50 (64%) | 2/50 (4%) | 11/18 (61%) | 5/19 (26%) |
| Control | |||||
| 8 | – | 23/53 (43%) | 2/53 (4%) | 2/10 (20%) | 0/10 (0%) |
| 9 | – | 9/26 (35%) | 0/28 (0%) | 4/12 (0%) | 0/12 (0%) |
| 10 | – | 15/45 (33%) | 4/45 (9%) | 20/39 (51%) | 7/39 (18%) |
| 11 | – | 14/49 (29%)* | 6/50 (12%)* | 19/36 (53%) | 7/36 (19%) |
| 12 | – | 15/53 (28%) | 4/53 (8%) | 18/32 (56%) | 2/32 (6%) |
| 13 | – | 8/34 (24%) | 0/34 (0%) | 6/14 (43%) | 0/14 (0%) |
| 14 | – | 6/42 (14%) | 0/42 (0%) | 5/13 (39%) | 1/13 (8%) |
TF ± TI = follicular trachoma and/or intense trachoma according to the WHO’s simplified grading system.
*
Missing data at time point. Values reflect the most recent study visit in the TANA II trial (i.e., last observation carried forward imputation); no mass azithromycin distribution was administered in the intervening time.